NASDAQ
115.07USD
+0.02 (+0.02%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.7B
P/E
—
EPS
—
Beta
0.25
52W range
50.85-115.13
Day range
115.03–115.07
Open
115.03
Prev close
115.05
Volume
13.2M
Avg volume
1.4M
Dividend
0.00
IPO
2022-02-04
https://www.defenseworld.net/2026/04/04/banque-pictet-cie-sa-acquires-shares-of-5109-arcellx-inc-aclx.html · 4/4/2026-0.30
https://www.defenseworld.net/2026/04/04/banque-pictet-cie-sa-has-287000-stake-in-ishares-u-s-regional-banks-etf-iat.html · 4/4/2026+0.30
https://www.marketwatch.com/story/these-2-chip-stocks-could-be-cheaper-ways-to-invest-in-a-hot-ai-trend-fc52000a · 3/28/2026+0.50
https://www.benzinga.com/trading-ideas/short-ideas/26/03/51033270/top-2-health-care-stocks-that-may-crash-this-quarter · 3/4/2026-0.60
https://www.globenewswire.com/news-release/2026/02/25/3244986/0/en/Veeco-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results.html · 2/25/2026+0.50
https://www.globenewswire.com/news-release/2026/02/23/3242727/0/en/Biotech-Breakthroughs-Big-Buyouts-Immunotherapy-Momentum-and-a-Media-Megamerger.html · 2/23/2026+0.90
https://www.fool.com/coverage/filings/2026/02/22/perceptive-advisors-dumps-1-million-aclx-shares/ · 2/22/2026-0.60
https://www.fool.com/coverage/filings/2026/01/31/arcellx-director-sells-6-000-shares-for-usd450-000/ · 2/1/2026-0.20
https://seekingalpha.com/article/4854003-arcellx-funded-into-2028-with-strong-clinical-data · 12/17/2025+1.00
https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/12/49265004/why-is-arcellx-stock-surging-today · 12/8/2025+1.00
https://seekingalpha.com/article/4850964-arcellx-inc-aclx-discusses-phase-2-immagineminus-1-study-results-and-multiple-myeloma · 12/7/2025+0.80
https://www.businesswire.com/news/home/20251206931756/en/Arcellx-Announces-New-Positive-Data-for-Its-iMMagine-1-Study-in-Patients-with-Relapsed-andor-Refractory-Multiple-Myeloma/ · 12/6/2025+1.00
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
